

The Path to
NEXT GENERATION
DRUG ELUTING STENT
TECHNOLOG

ESyne® stent —
the next generation drug
eluting stent with improved
performance and superior
clinical efficacy and safety¹.
Engineered on a clinically —
proven cobalt chromium
platform, the novel design
and **Formula X™** drug/
polymer coating technology
allows for thin struts, lowest
polymer load², and lowest drug
concentration² of any DES on
the market today.

DESyne® maximizes
deliverability and is able to
deliver superior performance
with **the lowest published
late lumen loss⁴**.

Engineered to maximize
**DELIVERABILITY &
CLINICAL PERFORMANCE**

DESyne®

NOVOLIMUS ELUTING CORONARY STENT SYSTEM

INNOVATING VASCULAR RESTORATION™
LEADING THE WAY TO NEXT GENERATION DES PLATFORMS

PRODUCT ORDERING INFORMATION						
Stent Diameter (mm)	Stent Length (mm)					
	14	18	23	28	32	38
2.5	SER2514	SER2518	SER2523	SER2528	SER2532	SER2538
2.75	SER2714	SER2718	SER2723	SER2728	SER2732	SER2738
3.0	SER3014	SER3018	SER3023	SER3028	SER3032	SER3038
3.5	SER3514	SER3518	SER3523	SER3528	SER3532	SER3538
4.0	SER4014	SER4018	SER4023	SER4028	SER4032	SER4038

Some sizes may not be available in all geographies.

INTERNATIONAL (OUS) USE ONLY

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Elixir Medical Corporation specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide.

Elixir Medical Corporate Headquarters
870 Hermosa Drive
Sunnyvale, CA 94085, USA
408.636.2000
info@elixirmedical.com



Elixir Medical Ireland
IDA Business and Technology Park
Carrick-on-Shannon
Co. Leitrim, Ireland
info@elixirmedical.com

DESyne®

NOVOLIMUS ELUTING CORONARY STENT SYSTEM

INNOVATING VASCULAR RESTORATION™
LEADING THE WAY TO NEXT GENERATION DES PLATFORMS



FORMULATM Coating Technology

Advanced Drug/Polymer Coating Technology


- » Thin polymer and drug matrix coating without the need for a primer coating
- » Superior DES clinical performance with excellent safety profile¹

Lowest Polymer Coating Load²

- » Reduced risk of adverse clinical events¹
- » Improved polymer biocompatibility³

Low Drug Dose


- » Sustainable performance with lower drug dose



UNIQUE Drug Agent


Proprietary Novolimus Drug Elution

- » Established safety and performance
 - Clinically proven 'olimus' drug family
 - Active metabolite of Sirolimus
- » Proprietary drug facilitates superior clinical efficacy¹
- » Potent anti-proliferative agent with known safety profile



Cobalt Chromium Platform


- » Lowest profile stent design² with ultra-thin struts (81 microns) for high flexibility and deliverability
- » Substantial vessel wall coverage for uniform drug delivery and open cell design for ease of side branch access



CLINICAL Performance Sets New Standards


EXCELLA II RCT (n = 210)

Late Lumen Loss at 9 Months




- » Significant reduction in late lumen loss, p = 0.001
- » Lowest published late lumen loss⁴

Major Adverse Cardiac Events (MACE) at 3 Years Clinical Follow-up




- » MACE defined as Target Lesion Revascularization, Cardiac Death and Myocardial Infarction

Clinical Follow-up year 1, 2 and 3




- » Sustained clinical performance over time

Neointimal Volume Obstruction by IVUS at 9 Months



- » Low neointimal volume obstruction

Neointima-free Frame Ratio [% cross-sections without neointima coverage]



- » Optimal neointimal coverage with low neointimal volume obstruction

1 » Serruys, P.W. et. al, EuroIntervention 2010.

2 » As compared to manufacturer reported thickness for Xience V® and Resolute®. Data on file at Elixir Medical.

3 » Data on file at Elixir Medical.

4 » As compared to manufacturer reported late lumen loss at follow up from similar trials. Data on file at Elixir Medical.

5 » SIRIUS: Weisz, G. et. al., JACC 2006 ; RESOLUTE: Serruys, P.W., EuroPCR 2009 ; SPIRIT III: Stone, G. W., Circulation 2009.

ENDEAVOR® and RESOLUTE® are registered trademark of Medtronic, XIENCE V® is registered trademark of Abbott Vascular, CYPHER® is registered trademark of Cordis Corporation.